Spruce Biosciences, Inc. (SPRB)
$42.87-2.68%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $59M
- Beta
- 3.30
- P/E (TTM)
- -1.05
- Short % float
- 47.48%
- Days to cover
- 4.5
- SI change
- +3.7%
- 1W
- -5.61%
- 1M
- -20.17%
- vs SPY 1W
- -6.04%
- vs SPY 1M
- -22.23%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 40
- VALUE
- 21
- GROWTH
- 47
- GARP
- 60
- TYPE
- Growth Compounder
Composite of Value · Growth · GARP
ROIC-74.1%
REV YoY-
ROE-123.5%
EPS YoY-
ROA-49.9%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-1.05
P/E FWD54.01
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.24
P/FCF-
EV/EBITDA-0.60
EV/EBIT-
PEG0.76
FCF YIELD-
RISK
INT COV-
D/E9.16
ALTMAN Z-
CURR RATIO9.23
ND/EBITDA-
BETA3.30
Company news
FAQ
- What is LOPJLB’s current signal on SPRB?
- LOPJLB’s latest quantitative signal on Spruce Biosciences, Inc. (SPRB) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is SPRB in?
- Spruce Biosciences, Inc. (SPRB) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Spruce Biosciences, Inc. (SPRB) do?
- Spruce Biosciences, Inc., founded in 2014 and situated in Daly City, California, operates as a biopharmaceutical enterprise. Its primary objective is to advance and bring to market innovative treatments, particularly for uncommon endocrine conditions. A central component of its therapeutic pipeline is tildacerfont, a non-steroidal drug candidate. This compound is currently undergoing Phase 2b c…